Precision BioSciences

Cindy Atwell, Chief Development Officer and Chief Business Officer

Oct. 6 | 11:45am | FLW Ballroom G

Durham, NC

(NASDAQ: DTIL)

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing in vivo gene correction therapies for rare and infectious diseases.

www.precisionbiosciences.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions